Mani Foroohar
Stock Analyst at Leerink Partners
(2.36)
# 2,484
Out of 5,179 analysts
171
Total ratings
47.92%
Success rate
-3.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $13.24 | +119.03% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $74.24 | +40.09% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $88.88 | +32.76% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $8.26 | +142.13% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $72.58 | +18.49% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $328.16 | +6.96% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $53.57 | -66.40% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $5.65 | +253.98% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $4.69 | +49.25% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $21.68 | -53.87% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $3.15 | +90.48% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $10.18 | +165.23% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $21.41 | +236.29% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $4.56 | +272.81% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $6.20 | +254.84% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.81 | +20.26% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $11.57 | +150.65% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $6.96 | +345.40% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.70 | +898.72% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $60.77 | -34.18% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.32 | +201.72% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $23.62 | +225.99% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.33 | +38.57% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $47.55 | +59.83% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.91 | +1,680.10% | 4 | May 12, 2022 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $13.24
Upside: +119.03%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $74.24
Upside: +40.09%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $88.88
Upside: +32.76%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $8.26
Upside: +142.13%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $72.58
Upside: +18.49%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $328.16
Upside: +6.96%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $53.57
Upside: -66.40%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $5.65
Upside: +253.98%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $4.69
Upside: +49.25%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $21.68
Upside: -53.87%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.15
Upside: +90.48%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $10.18
Upside: +165.23%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $21.41
Upside: +236.29%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.56
Upside: +272.81%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.20
Upside: +254.84%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.81
Upside: +20.26%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $11.57
Upside: +150.65%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $6.96
Upside: +345.40%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.70
Upside: +898.72%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $60.77
Upside: -34.18%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.32
Upside: +201.72%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $23.62
Upside: +225.99%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.33
Upside: +38.57%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $47.55
Upside: +59.83%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.91
Upside: +1,680.10%